Development of a nanoparticulate formulation of diminazene to treat African trypanosomiasis

Nanotechnology

Volumn 21, Issue 50, 2010, Pages

  Kroubi, Maya ^a   Daulouede, Sylvie ^b   Karembe, Hamadi ^c   Jallouli, Youssef ^d   Howsam, Mike ^d   Mossalayi, Djavad ^b   Vincendeau, Philippe ^b   Betbeder, Didier ^a,e  

^a UFR3S Pharmacie   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CEVA SANTÉ ANIMALE   (France)

^d UNIV LILLE   (France)

^e UNIVERSITÉ D'ARTOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPIDS;

CATIONIC NANOPARTICLES; DRUG CANDIDATES; DRUG DELIVERY SYSTEM; DRUG ENTRAPMENT; IN-VITRO TESTS; LOADING TECHNIQUE; NANO PARTICULATES; THERAPEUTIC STRATEGY;

DRUG DELIVERY;

ANTITRYPANOSOMAL AGENT; DIMINAZENE; NANOPARTICLE; PHOSPHOLIPID;

AFRICAN TRYPANOSOMIASIS; ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG STABILITY; MOUSE; OXIDATION REDUCTION REACTION; TRYPANOSOMA BRUCEI;

ANIMALS; DIMINAZENE; DRUG DELIVERY SYSTEMS; DRUG STABILITY; MICE; NANOPARTICLES; OXIDATION-REDUCTION; PHOSPHOLIPIDS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 78650106561     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/21/50/505102     Document Type: Article

References (25)

1. Miller E N, Allan L M and Turner M J 1984 Topological analysis of antigenic determinants on a variant surface glycoprotein of Trypanosoma brucei Mol. Biochem. Parasitol. 13 67-81 (Pubitemid 14024947)
2. Apted F I 1965 Trypanosomiasis. African trypanosomiasis: human Trop. Dis. Bull. 62 369-83
3. Barrett M P, Boykin D W, Brun R and Tidwell R R 2007 Human African trypanosomiasis: pharmacological re-engagement with a neglected disease Br. J. Pharmacol. 152 1155-71 (Pubitemid 350242432)
4. Bouteille B, Oukem O, Bisser S and Dumas M 2003 Treatment perspectives for human African trypanosomiasis Fundam. Clin. Pharmacol. 17 171-81 (Pubitemid 36513208)
5. Carter N S, Berger B J and Fairlamb A H 1995 Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and-resistant Trypanosoma brucei brucei J. Biol. Chem. 270 28153-7
6. Carter N S and Fairlamb A H 1993 Arsenical-resistant trypanosomes lack an unusual adenosine transporter Nature 361 173-6 (Pubitemid 23031354)
7. Hay R J 1994 Liposomal amphotericin B, AmBisome J. Infect. 28 35-43
8. Cauchetier E, Deniau M, Fessi H, Astier A and Paul M 2003 Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics Int. J. Pharm. 250 273-81 (Pubitemid 35447956)
9. Durand R, Paul M, Rivollet D, Fessi H, Houin R, Astier A and Deniau M 1997 Activity of pentamidine-loaded poly (D, L-lactide) nanoparticles against Leishmania infantum in a murine model Parasite 4 331-6 (Pubitemid 127497638)
10. Durand R, Paul M, Rivollet D, Houin R, Astier A and Deniau M 1997 Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model Int. J. Parasitol. 27 1361-7 (Pubitemid 27502238)
11. Jennings F W and Gray G D 1983 Relapsed parasitaemia following chemotherapy of chronic T.brucei infections in mice and its relation to cerebral trypanosomes Contrib. Microbiol. Immunol. 7 147-54
12. Jallouli Y, Paillard A, Chang J, Sevin E and Betbeder D 2007 Influence of surface charge and inner composition of porous nanoparticles to cross blood-brain barrier in vitro Int. J. Pharm. 344 103-9 (Pubitemid 47495981)
13. Paillard A, Passirani C, Saulnier P, Kroubi M, Garcion E, Benoit J P and Betbeder D 2009 Positively-charged, porous, polysaccharide nanoparticles loaded with anionic molecules behave as 'stealth' cationic nanocarriers Pharmacol. Res. 27 126-33
14. Pilch D S, Kirolos M A, Liu X, Plum G E and Breslauer K J 1995 Berenil [1, 3-bis (4′-amidinophenyl) triazene] binding to DNA duplexes and to a RNA duplex: evidence for both intercalative and minor groove binding properties Biochemistry 34 9962-76
15. Campbell M, Prankerd R J, Davie A S and Charman W N 2004 Degradation of berenil (diminazene aceturate) in acidic aqueous solution J. Pharm. Pharmacol. 56 1327-32 (Pubitemid 39369005)
16. Clement B, Immel M and Raether W 1992 Metabolic N-hydroxylation of diminazene in vitro Arzneimittelforschung 42 1497-504 (Pubitemid 23007374)
17. Major M, Prieur E, Tocanne J F, Betbeder D and Sautereau A M 1997 Characterization and phase behaviour of phospholipid bilayers adsorbed on spherical polysaccharidic nanoparticles Biochim. Biophys. Acta 1327 32-40 (Pubitemid 27283396)
18. Olbrich C, Gessner A, Schroder W, Kayser O and Muller R H 2004 Lipid-drug conjugate nanoparticles of the hydrophilic drug diminazene-cytotoxicity testing and mouse serum adsorption J. Control. Release 96 425-35 (Pubitemid 38553921)
19. Atsriku C, Watson D G, Tettey J N, Grant M H and Skellern G G 2002 Determination of diminazene aceturate in pharmaceutical formulations by HPLC and identification of related substances by LC/MS J. Pharm. Biomed. Anal. 30 979-86 (Pubitemid 35284309)
20. Widdop B 1986 Hospital Toxicology and Drug Abuse Screening. Clarke's Isolation and Identification of Drugs (London: The Pharmaceutical Press) pp 18-19
21. Weng Larsen S and Larsen C 2009 Critical factors influencing the in vivo performance of long-acting lipophilic solutions-impact on in vitro release method design AAPS J. 11 762-70
22. Lanham S M 1968 Separation of trypanosomes from the blood of infected rats and mice by anion-exchangers Nature 218 1273-4
23. Abrahamsohn IA and Silva W D 1977 Antibody dependent cell-mediated cytotoxicity against Trypanosoma cruzi Parasitology 75 317-23 (Pubitemid 8231346)
24. Paul M, Fessi H, Laatiris A, Boulard Y, Durand R, Deniau M and Astier A 1997 Pentamidine-loaded poly (D, L-lactide) nanoparticles: physicochemical properties and stability work Int. J. Pharm. 159 223-32 (Pubitemid 28055858)
25. Yoshihara E, Tachibana H and Nakae T 1987 Trypanocidal activity of the stearylamine-bearing liposome in vitro Life Sci. 40 2153-9 (Pubitemid 17082407)